未登录Planning and Implementing Master Protocol Trials in Japan: Key Considerations of the Japanese Guideline
Hirakawa, Akihiro; Asakawa, Takashi; Tokushige, Kota; Ozaki, Ryoto; Yoshida, Mizuki; Okuma, Hitomi Sumiyoshi; Saito, Sho; Shimizu, Yosuke; Kitabayashi, Ryo; Hanazawa, Ryoichi; Sato, Hiroyuki; Uemura, Yukari .png)
分享.png)
收藏Summary Report of a Public Workshop: Case Studies of Multi-Regional Clinical Trial Incorporating Concept of the ICH E17 GuidelineMatsushima, Nobuko; Otsubo, Yasuto; Aoi, Yoko; Nakamura, Ryuta; Kaneko, Shuhei; Asakawa, Takashi; Matsuoka, Nobushige; Watabe, Kei; Komiyama, Osamu; Yamamoto, Hideharu; Ando, Yuki 分享 收藏 Magnetoencephalographic brain activity evoked by the optic-flow task is correlated with β-amyloid burden and parahippocampal atrophyTsuchimine, Shoko; Kudo, Kiwamu; Komatsu, Junji; Shibata, Shutaro; Kitagawa, Sachiko; Misaka, Yoshihiro; Noguchi-Shinohara, Moeko; Ono, Kenjiro; Morise, Hirofumi; Asakawa, Takashi 分享 收藏 Impact of Bevacizumab Being Skipped due to Adverse Events of Special Interest for Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab: An Exploratory Analysis of the Phase III IMbrave150 studyKudo, Masatoshi; Tsuchiya, Kaoru; Shao, Yu-Yun; Finn, Richard S.; Galle, Peter R.; Ducreux, Michel; Cheng, Ann-Lii; Yamashita, Tatsuya; Koga, Hironori; Take, Ryosuke; Yamada, Kyoko; Asakawa, Takashi; Nakagawa, Yuki; Ikeda, Masafumi 分享 收藏 IMbrave150: Exploratory analyses for investigating associations between overall survival (OS) and depth of response (DpR) or duration of response (DoR) in patients (pts) with unresectable hepatocellular carcinoma (HCC)Kudo, M.; Yamashita, T.; Finn, R. S.; Galle, P. R.; Ducreux, M. P.; Cheng, A-L.; Tsuchiya, K.; Sakamoto, N.; Hige, S.; Take, R.; Yamada, K.; Asakawa, T.; Nakagawa, Y.; Ikeda, M. 分享 收藏 分享 收藏 分享 收藏 分享 收藏 Circulating tumor DNA-guided treatment with pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer: a phase 2 trial循环肿瘤DNA指导下帕妥珠单抗联合曲妥珠单抗治疗HER2-amplified转移性结直肠癌的2期临床试验Nakamura, Yoshiaki; Okamoto, Wataru; Kato, Takeshi; Esaki, Taito; Kato, Ken; Komatsu, Yoshito; Yuki, Satoshi; Masuishi, Toshiki; Nishina, Tomohiro; Ebi, Hiromichi; Sawada, Kentaro; Taniguchi, Hiroya; Fuse, Nozomu; Nomura, Shogo; Fukui, Makoto; Matsuda, Seiko; Sakamoto, Yasutoshi; Uchigata, Hiroshi; Kitajima, Kana; Kuramoto, Naomi; Asakawa, Takashi; Olsen, Steve; Odegaard, Justin, I; Sato, Akihiro; Fujii, Satoshi; Ohtsu, Atsushi; Yoshino, Takayuki 分享 收藏 The efficacy and safety of pertuzumab plus trastuzumab and docetaxel as a first-line therapy in Japanese patients with inoperable or recurrent HER2-positive breast cancer: the COMACHI study帕妥珠单抗联合曲妥珠单抗和多西他赛作为一线治疗日本不能手术或复发的HER2-positive乳腺癌患者的疗效和安全性: COMACHI研究Takahashi, Masato; Ohtani, Shoichiro; Nagai, Shigenori E.; Takashima, Seiki; Yamaguchi, Miki; Tsuneizumi, Michiko; Komoike, Yoshifumi; Osako, Tomofumi; Ito, Yoshinori; Ikeda, Masahiko; Ishida, Kazushige; Nakayama, Takahiro; Takashima, Tsutomu; Asakawa, Takashi; Matsumoto, Sho; Shimizu, Daisuke; Masuda, Norikazu 分享 收藏 分享 收藏 分享 收藏 Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trialHida, Toyoaki; Nokihara, Hiroshi; Kondo, Masashi; Kim, Young Hak; Azuma, Koichi; Seto, Takashi; Takiguchi, Yuichi; Nishio, Makoto; Yoshioka, Hiroshige; Imamura, Fumio; Hotta, Katsuyuki; Watanabe, Satoshi; Goto, Koichi; Satouchi, Miyako; Kozuki, Toshiyuki; Shukuya, Takehito; Nakagawa, Kazuhiko; Mitsudomi, Tetsuya; Yamamoto, Nobuyuki; Asakawa, Takashi; Asabe, Ryoichi; Tanaka, Tomohiro; Tamura, Tomohide 分享 收藏 Phase III clinical trials in chemotherapy-naive patients with advanced NSCLC assessing the combination of atezolizumab and chemotherapyReck, M.; Papadimitrakopoulou, V. A.; Cappuzzo, F.; Jotte, R.; Mok, T. S. K.; Sandler, A.; Waterkamp, D.; Coleman, S.; Asakawa, T.; Socinski, M. 分享 收藏 Updated Data of a Phase 1/2 Study (AF-001JP) of Alectinib, a CNS-Penetrant, Highly Selective ALK Inhibitor in ALK-rearranged Advanced NSCLCTamura, T.; Seto, T.; Nakagawa, K.; Maemondo, M.; Inoue, A.; Hida, T.; Yoshioka, H.; Harada, M.; Ohe, Y.; Nogami, N.; Murakami, H.; Takeuchi, K.; Asakawa, T.; Kikuchi, K.; Tanaka, T.; Nishio, M. 分享 收藏 分享 收藏 Randomised phase III trial of carboplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive disease small-cell lung cancer: JCOG 9702卡铂联合依托泊苷与分次顺铂联合依托泊苷在患有广泛疾病小细胞肺癌的老年或低风险患者中的随机III期试验: JCOG 9702Okamoto, H.; Watanabe, K.; Kunikane, H.; Yokoyama, A.; Kudoh, S.; Asakawa, T.; Shibata, T.; Kunitoh, H.; Tamura, T.; Saijo, N. 分享 收藏 
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
